Several nonselective or semiselective HDAC inhibitors, including romidepsin (7, 8), vorinostat (9, 10), and panobinostat (11), have demonstrated varying clinical benefit in combination with bortezomib (BTZ) and dexamethasone for MM. This evidence concerns the gene HDAC9 and Miyoshi myopathy.